Back

Therapeutic effects of phosphodiesterase 5 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF) and combined post- and pre-capillary pulmonary hypertension (Cpc-PH).

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Pulmonary hypertension: pathophysiology Chronic pulmonary hypertension ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Tilmann Kramer

Cologne University Hospital - Heart Center, Cologne (Germany)

9 More presentations in this session

Presentation thumbnail
Contribution of right ventricular deformation analysis to screening of pulmonary hypertension in patients with systemic sclerosis and mixed connective tissue disease
Doctor J. Latal (Olomouc, CZ)
Abstract Slides
Presentation thumbnail
Role of endothelial transforming growth factor-beta signalling for chronic fibrotic remodelling in murine and human venous thrombosis
Professor K. Schaefer (Mainz, DE)
Abstract
Presentation thumbnail
Pulmonary vascular gradients, right ventricular afterload and outcomes in pulmonary hypertension due to left heart disease
Associate Professor S. Caravita (Bergamo, IT)
Abstract
Presentation thumbnail
Non invasive discrimination between pre and post capillary pulmonary hypertension : comparison of three published scores
Doctor O. Raitiere (Le Havre Cedex, FR)
Abstract
Presentation thumbnail
Pulmonary hypertension due to diastolic dysfunction: a predictive model using the national echo database of australia (NEDA)
Doctor K. Chung (PERTH, AU)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3 - Pulmonary hypertension: pathophysiology

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources